DIHUA YU to Female
This is a "connection" page, showing publications DIHUA YU has written about Female.
Connection Strength
0.390
-
Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition. Nat Cell Biol. 2024 Oct; 26(10):1773-1789.
Score: 0.027
-
EZH2 engages TGF? signaling to promote breast cancer bone metastasis via integrin ?1-FAK activation. Nat Commun. 2022 05 10; 13(1):2543.
Score: 0.023
-
Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. Cancer Res. 2019 08 15; 79(16):4211-4226.
Score: 0.019
-
Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention. Cancer Prev Res (Phila). 2017 Nov; 10(11):641-650.
Score: 0.017
-
Advances in decoding breast cancer brain metastasis. Cancer Metastasis Rev. 2016 12; 35(4):677-684.
Score: 0.016
-
Upregulation of lactate dehydrogenase a by 14-3-3? leads to increased glycolysis critical for breast cancer initiation and progression. Oncotarget. 2016 Jun 07; 7(23):35270-83.
Score: 0.015
-
Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. Cancer Res. 2015 Nov 15; 75(22):4863-75.
Score: 0.014
-
14-3-3? turns TGF-?'s function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell. 2015 Feb 09; 27(2):177-92.
Score: 0.014
-
PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biol Ther. 2015; 16(3):402-11.
Score: 0.014
-
Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Res. 2014 May; 24(5):542-59.
Score: 0.013
-
Enhanced PI3K p110a signaling confers acquired lapatinib resistance that can be effectively reversed by a p110a-selective PI3K inhibitor. Mol Cancer Ther. 2014 Jan; 13(1):60-70.
Score: 0.013
-
14-3-3? orchestrates mammary tumor onset and progression via miR-221-mediated cell proliferation. Cancer Res. 2014 Jan 01; 74(1):363-373.
Score: 0.013
-
SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res. 2013 Sep 15; 73(18):5764-74.
Score: 0.012
-
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res. 2012 Sep 01; 72(17):4417-28.
Score: 0.012
-
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011 Apr; 17(4):461-9.
Score: 0.011
-
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010 Oct; 177(4):1647-56.
Score: 0.010
-
Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene. 2006 Jun 01; 25(23):3286-95.
Score: 0.007
-
Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation. Int J Biol Sci. 2023; 19(10):2957-2973.
Score: 0.006
-
Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med. 2022 11 02; 14(669):eabo1981.
Score: 0.006
-
Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022 10; 3(10):1211-1227.
Score: 0.006
-
Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene. 2001 Dec 06; 20(56):8066-74.
Score: 0.006
-
Targeting the av integrin/TGF-? axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest. 2021 07 15; 131(14).
Score: 0.005
-
Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nat Commun. 2021 05 13; 12(1):2788.
Score: 0.005
-
Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathol. 2021 02; 141(2):303-321.
Score: 0.005
-
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000 Dec 11; 19(53):6115-21.
Score: 0.005
-
Role of erbB2 in breast cancer chemosensitivity. Bioessays. 2000 Jul; 22(7):673-80.
Score: 0.005
-
Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Res. 1999 Apr 01; 59(7):1620-5.
Score: 0.005
-
Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 1998 Apr 23; 16(16):2087-94.
Score: 0.004
-
JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017 12 01; 127(12):4498-4515.
Score: 0.004
-
Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1) J Natl Cancer Inst. 1997 Oct 15; 89(20):1524-9.
Score: 0.004
-
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res. 2017 10 01; 77(19):5374-5383.
Score: 0.004
-
Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997 Mar 15; 57(6):1199-205.
Score: 0.004
-
New strategies in locally advanced breast cancer. Cancer Treat Res. 1997; 90:253-71.
Score: 0.004
-
Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016 Dec 12; 30(6):925-939.
Score: 0.004
-
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632.
Score: 0.004
-
Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene. 1995 Oct 05; 11(7):1383-8.
Score: 0.004
-
HER-2/neu-targeting gene therapy--a review. Gene. 1995 Jun 14; 159(1):65-71.
Score: 0.004
-
HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol. 2015 Mar; 9(3):586-600.
Score: 0.003
-
MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Sci Signal. 2014 Jul 29; 7(336):ra71.
Score: 0.003
-
Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. PLoS One. 2014; 9(7):e101452.
Score: 0.003
-
Definition of PKC-a, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res. 2014 Sep 01; 74(17):4822-35.
Score: 0.003
-
Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLoS One. 2013; 8(9):e73406.
Score: 0.003
-
Multiple target-specific molecular agents for detection and image analysis of breast cancer characteristics in mice. Curr Mol Med. 2013 Mar; 13(3):446-58.
Score: 0.003
-
Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993 Feb 15; 53(4):891-8.
Score: 0.003
-
Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene. 1992 Nov; 7(11):2263-70.
Score: 0.003
-
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012 May 25; 149(5):1098-111.
Score: 0.003
-
Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene. 1991 Nov; 6(11):1991-6.
Score: 0.003
-
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011 Aug 10; 29(23):3126-32.
Score: 0.003
-
Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray. Technol Cancer Res Treat. 2006 Dec; 5(6):543-51.
Score: 0.002
-
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006 May; 3(5):269-80.
Score: 0.002
-
E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. Breast Cancer. 2001; 8(4):285-93.
Score: 0.001
-
C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene. 2000 Oct 05; 19(42):4864-75.
Score: 0.001
-
Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. Cancer Gene Ther. 2000 Mar; 7(3):422-9.
Score: 0.001
-
E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9.
Score: 0.001
-
Isolated limb perfusion in the sarcoma-bearing rat: a novel preclinical gene delivery system. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2197-203.
Score: 0.001
-
Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. Clin Cancer Res. 1997 Nov; 3(11):2017-24.
Score: 0.001
-
Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene. 1997 Apr 24; 14(16):1965-71.
Score: 0.001
-
HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene. 1995 May 18; 10(10):1947-54.
Score: 0.001